Showing results (281-290 of 981) with videos related to

Sort By:
Pageof 99
Cardiovascular Therapeutics|December 31, 2019
Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin TherapyMyung Han Hyun, Yuchang Lee, Byoung Geol Choi, et al.
Cardiovascular Therapeutics|March 2, 2018
Efficacy and safety of a second-generation biodegradable polymer sirolimus-eluting stent: One-year results of the CREDIT 2 trialKai Xu, Yaling Han, Bo Xu, et al.
Cardiovascular Therapeutics|June 22, 2016
Adenosine triphosphate postconditioning is associated with better preserved global and regional cardiac function during myocardial ischemia and reperfusion: a speckle tracking imaging-based echocardiologic studyMin Ren, Yujie Liu, Huiya Zhao, et al.
Cardiovascular Therapeutics|December 29, 2017
Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activationWojciech Garczorz, Enrique Gallego-Colon, Agnieszka Kosowska, et al.
Cardiovascular Therapeutics|October 21, 2018
Effects of serial phlebotomy on vascular endothelial function: Results of a prospective double-blind randomized studyQurat-Ul-Ain Jelani, Bhisham Harchandani, Ritchard G Cable, et al.
Cardiovascular Therapeutics|October 30, 2018
The modifying effect of the MTHFR genotype on the association between folic acid supplementation and pulse wave velocity: Findings from the CSPPTXin Yang, Minghua Zhang, Rensheng Song, et al.
Cardiovascular Therapeutics|April 20, 2017
RVX 208: A novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyondGopal C Ghosh, Rajarshi Bhadra, Raktim K Ghosh, et al.
Cardiovascular Therapeutics|November 19, 2016
Ezetimibe: Use, costs, and adverse events in AustraliaSamantha A Hollingworth, Remo Ostino, Michael C David, et al.
Cardiovascular Therapeutics|November 19, 2016
Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trialGiuseppe Derosa, Pamela Maffioli, Maria D'Avino, et al.
Cardiovascular Therapeutics|October 30, 2016
Platelet activating factor: A potential biomarker in acute coronary syndrome?Anand Vijaya Kumar Palur Ramakrishnan, Treesa P Varghese, Sreedevi Vanapalli, et al.
Pageof 99